Related Experiment Video

Updated: Jul 19, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Poly(ADP-ribose)polymerase inhibition decreases angiogenesis

Mohanraj Rajesh1, Partha Mukhopadhyay, Grzegorz Godlewski

  • 1Laboratory of Physiological Studies, NIAAA, National Institutes of Health, Bethesda, MD, USA.

Biochemical and Biophysical Research Communications
|October 19, 2006
PubMed

Insights

Poly(ADP-ribose)polymerase (PARP) inhibitors reduce cancer cell growth by inhibiting angiogenesis. These findings suggest PARP inhibitors may offer new treatments for cancers and related conditions.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Poly(ADP-ribose)polymerase (PARP) is a nuclear enzyme crucial for DNA repair and cell death regulation.
  • PARP inhibitors show promise in cancer therapy, both alone and with other treatments.
  • Previous studies indicated PARP inhibition affects endothelial cell functions.

Purpose of the Study:

  • To investigate the antiangiogenic effects of potent PARP inhibitors.
  • To evaluate the impact of 5-aminoisoquinolinone-hydrochloride (5-AIQ) and 1,5-isoquinolinediol (IQD) on endothelial cell behavior.
  • To explore the potential of PARP inhibitors in cancer treatment beyond their DNA repair roles.

Main Methods:

  • In vitro assays using human umbilical vein endothelial cells (HUVECs) to assess proliferation, migration, and tube formation.
  • Stimulation of HUVECs with vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF).
  • Ex vivo rat aortic ring assay to evaluate the effect of PARP inhibitors on angiogenesis.

Main Results:

  • 5-AIQ and IQD demonstrated a dose-dependent reduction in VEGF- and bFGF-induced HUVEC proliferation, migration, and tube formation.
  • PARP inhibitors effectively prevented sprouting in the rat aortic ring explant model, indicating antiangiogenic activity.
  • The study confirmed the antiangiogenic properties of PARP inhibitors in vitro and ex vivo.

Conclusions:

  • PARP inhibitors possess significant antiangiogenic effects.
  • These antiangiogenic properties present a novel therapeutic strategy for various cancers and related conditions like tumor metastases and retinopathies.
  • Targeting angiogenesis via PARP inhibition could broaden the clinical applications of these agents in oncology.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...